Kathryn Falberg

Ms. Kathryn E.
Falberg is an Independent Director at Nuvation Bio, Inc. and an Independent Director at Arcus Biosciences, Inc. She is on the Board of Directors at Nuvation Bio, Inc., Arcus Biosciences, Inc. and Nuvation Bio Operating Co., Inc. Ms. Falberg was previously employed as an Independent Director by Tricida, Inc., an Independent Director by UroGen Pharma Ltd., an Independent Director by The Trade Desk, Inc., an Independent Director by Aimmune Therapeutics, Inc., a Chairman by aTyr Pharma, Inc., an Independent Director by Medivation LLC (California), a Chief Financial Officer & Senior Vice President by Azur Pharma Ltd., a Chief Financial Officer & Executive Vice President by Jazz Pharmaceuticals Plc, a Chief Financial Officer & Executive Vice President by Jazz Pharmaceuticals, Inc., an Independent Director by QLT, Inc., a Chief Operating & Financial Officer by ARCA biopharma, Inc., a Chairman by Halozyme Therapeutics, Inc., a President by Canyon Capital & Consulting, Inc., a Chief Financial Officer by Inamed Corp., a Chief Financial Officer, SVP-Finance & Strategy by Amgen, Inc., a Chief Financial Officer & Director by AdECN, Inc., and a Chief Financial Officer, Treasurer & VP by Applied Magnetics Corp.
She also served on the board at Axovant Sciences, Inc., Axovant Gene Therapies Ltd., BioMarin Pharmaceutical, Inc., Ariosa Diagnostics, Inc., Medivation, Inc. /Old/, Human Genome Sciences, Inc., Fresh Del Monte Produce, Inc., AMO Manufacturing USA LLC, ESS Technology, Inc. and Roivant Sciences GmbH.
She received her undergraduate degree from the University of California, Los Angeles and an MBA from the University of California, Los Angeles.